Unusual Suspects in the Twilight Zone Between the Hsp90 Interactome and Carcinogenesis

Advances in Cancer Research

Volumn 129, Issue , 2016, Pages 1-30

  Vartholomaiou, Evangelia ^a   Echeverría, Pablo C ^a   Picard, Didier ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Hsp90; Kinase; Molecular chaperone; Oncogene; Protein protein interaction; Regulation; Transcription factor; Tumor suppressor

Indexed keywords

APC PROTEIN; BETA ARRESTIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; DEATH ASSOCIATED PROTEIN KINASE; DISCOIDIN; DISCOIDIN DOMAIN RECEPTOR 1; DISCOIDIN DOMAIN RECEPTOR 2; DNA HELICASE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; EPHRIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; HELICASE; HIGH MOBILITY GROUP A PROTEIN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLTRANSFERASE; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHOTRANSFERASE; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BLOOM SYNDROME HELICASE; BRMS1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CELL RECEPTOR; CHAPERONE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; EXPORTIN 1 PROTEIN; HISTONE LYSINE METHYLTRANSFERASE; KARYOPHERIN; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; ONCOPROTEIN; PHARMACOLOGICAL BIOMARKER; PRMT5 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; RECQ HELICASE; REPRESSOR PROTEIN; SIGNAL PEPTIDE; SMYD3 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

CARCINOGENESIS; CELL DEATH; GERM CELL TUMOR; HUMAN; LEUKEMIA; MITOSIS; MULTIPLE CANCER; NONHUMAN; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; NEOPLASMS;

APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BIOMARKERS, PHARMACOLOGICAL; CARCINOGENESIS; CELL CYCLE PROTEINS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; HISTONE-LYSINE N-METHYLTRANSFERASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KARYOPHERINS; MOLECULAR CHAPERONES; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN-ARGININE N-METHYLTRANSFERASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECQ HELICASES; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84951161372     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acr.2015.08.001     Document Type: Chapter

References (147)

1. Alexander J.M., Bikkal H.A., Zervas N.T., Laws E.R., Klibanski A. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-β receptors in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1996, 81:783-790.
2. Al-Hakim A.K., Goransson O., Deak M., Toth R., Campbell D.G., Morrice N.A., et al. 14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK. Journal of Cell Science 2005, 118:5661-5673.
3. Annamalai B., Liu X., Gopal U., Isaacs J.S. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: Implications for cancer cell migration and metastasis. Molecular Cancer Research 2009, 7:1021-1032.
4. Arevalo J.C., Wu S.H. Neurotrophin signaling: Many exciting surprises!. Cellular and Molecular Life Sciences 2006, 63:1523-1537.
5. Bae D.H., Jansson P.J., Huang M.L., Kovacevic Z., Kalinowski D., Lee C.S., et al. The role of NDRG1 in the pathology and potential treatment of human cancers. Journal of Clinical Pathology 2013, 66:911-917.
6. Bansal H., Bansal S., Rao M., Foley K.P., Sang J., Proia D.A., et al. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood 2010, 116:4591-4599.
7. Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003, 300:949.
8. Barrios-Rodiles M., Brown K.R., Ozdamar B., Bose R., Liu Z., Donovan R.S., et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 2005, 307:1621-1625.
9. Bernstein S.L., Russell P., Wong P., Fishelevich R., Smith L.E. Heat shock protein 90 in retinal ganglion cells: Association with axonally transported proteins. Visual Neuroscience 2001, 18:429-436.
10. Bhattacharyya S., Keirsey J., Russell B., Kavecansky J., Lillard-Wetherell K., Tahmaseb K., et al. Telomerase-associated protein 1, HSP90, and topoisomerase IIα associate directly with the BLM helicase in immortalized cells using ALT and modulate its helicase activity using telomeric DNA substrates. Journal of Biological Chemistry 2009, 284:14966-14977.
11. Bialik S., Kimchi A. The death-associated protein kinases: Structure, function, and beyond. Annual Review of Biochemistry 2006, 75:189-210.
12. Bouwmeester T., Bauch A., Ruffner H., Angrand P.O., Bergamini G., Croughton K., et al. A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nature Cell Biology 2004, 6:97-105.
13. Bowers A.J., Boylan J.F. Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene 2004, 328:135-142.
14. Bradley E., Bieberich E., Mivechi N.F., Tangpisuthipongsa D., Wang G. Regulation of embryonic stem cell pluripotency by heat shock protein 90. Stem Cells 2012, 30:1624-1633.
15. Brosens L.A., van Hattem A., Hylind L.M., Iacobuzio-Donahue C., Romans K.E., Axilbund J., et al. Risk of colorectal cancer in juvenile polyposis. Gut 2007, 56:965-967.
16. Brown M.A., Foreman K., Harriss J., Das C., Zhu L., Edwards M., et al. C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis. Oncotarget 2015, 6:4005-4019.
17. src, with two cellular proteins. Cell 1981, 25:363-372.
18. Brun M., Coles J.E., Monckton E.A., Glubrecht D.D., Bisgrove D., Godbout R. Nuclear factor I regulates brain fatty acid-binding protein and glial fibrillary acidic protein gene expression in malignant glioma cell lines. Journal of Molecular Biology 2009, 391:282-300.
19. Burroughs S.K., Kaluz S., Wang D., Wang K., Van Meir E.G., Wang B. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Medicinal Chemistry 2013, 5:553-572.
20. Cascon A., Robledo M. MAX and MYC: A heritable breakup. Cancer Research 2012, 72:3119-3124.
21. Chan S.W., Lim C.J., Chen L., Chong Y.F., Huang C., Song H., et al. The Hippo pathway in biological control and cancer development. Journal of Cellular Physiology 2011, 226:928-939.
22. Chariot A. The NF-κB-independent functions of IKK subunits in immunity and cancer. Trends in Cell Biology 2009, 19:404-413.
23. Chen G., Cao P., Goeddel D.V. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Molecular Cell 2002, 9:401-410.
24. Citri A., Harari D., Shohat G., Ramakrishnan P., Gan J., Lavi S., et al. Hsp90 recognizes a common surface on client kinases. Journal of Biological Chemistry 2006, 281:14361-14369.
25. Cleynen I., Van de Ven W.J. The HMGA proteins: A myriad of functions (review). International Journal of Oncology 2008, 32:289-305.
26. Craven R.J., Cance W.G., Liu E.T. The nuclear tyrosine kinase Rak associates with the retinoblastoma protein pRb. Cancer Research 1995, 55:3969-3972.
27. Croteau D.L., Popuri V., Opresko P.L., Bohr V.A. Human RecQ helicases in DNA repair, recombination, and replication. Annual Review of Biochemistry 2014, 83:519-552.
28. Culig Z., Santer F.R. Androgen receptor signaling in prostate cancer. Cancer Metastasis Reviews 2014, 33:413-427.
29. Dai B., Gong A., Jing Z., Aldape K.D., Kang S.H., Sawaya R., et al. Forkhead box M1 is regulated by heat shock factor 1 and promotes glioma cells survival under heat shock stress. Journal of Biological Chemistry 2013, 288:1634-1642.
30. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Research 2005, 65:7591-7595.
31. Declercq W., Vanden Berghe T., Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell 2009, 138:229-232.
32. De Nardo D., Masendycz P., Ho S., Cross M., Fleetwood A.J., Reynolds E.C., et al. A central role for the Hsp90.Cdc37 molecular chaperone module in interleukin-1 receptor-associated-kinase-dependent signaling by toll-like receptors. Journal of Biological Chemistry 2005, 280:9813-9822.
33. Dulloo I., Phang B.H., Othman R., Tan S.Y., Vijayaraghavan A., Goh L.K., et al. Hypoxia-inducible TAp73 supports tumorigenesis by regulating the angiogenic transcriptome. Nature Cell Biology 2015, 17:511-523.
34. Echeverria P.C., Bernthaler A., Dupuis P., Mayer B., Picard D. An interaction network predicted from public data as a discovery tool: Application to the Hsp90 molecular chaperone machine. PLoS One 2011, 6:e26044.
35. Echeverria P.C., Picard D. A global view of the proteome perturbations by Hsp90 inhibitors. The molecular chaperones interaction networks in protein folding and degradation 2014, Vol. 1:133-149. Springer, New York. W.A. Houry (Ed.).
36. Falsone S.F., Gesslbauer B., Tirk F., Piccinini A.M., Kungl A.J. A proteomic snapshot of the human heat shock protein 90 interactome. FEBS Letters 2005, 579:6350-6354.
37. Fang M., Ou J., Hutchinson L., Green M.R. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG island methylator phenotype. Molecular Cell 2014, 55:904-915.
38. Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death and Differentiation 2007, 14:400-410.
39. Fierro-Monti I., Echeverria P., Racle J., Hernandez C., Picard D., Quadroni M. Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy. PLoS One 2013, 8:e80425.
40. Forbes S., Clements J., Dawson E., Bamford S., Webb T., Dogan A., et al. Cosmic 2005. British Journal of Cancer 2006, 94:318-322.
41. Giaginis C., Tsourouflis G., Zizi-Serbetzoglou A., Kouraklis G., Chatzopoulou E., Dimakopoulou K., et al. Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathology Oncology Research 2010, 16:267-276.
42. Gradin K., McGuire J., Wenger R.H., Kvietikova I., Whitelaw M.L., Toftgard R., et al. Functional interference between hypoxia and dioxin signal transduction pathways: Competition for recruitment of the Arnt transcription factor. Molecular and Cellular Biology 1996, 16:5221-5231.
43. Guo D., Bell E.H., Mischel P., Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Current Pharmaceutical Design 2014, 20:2619-2626.
44. Hacker H., Karin M. Regulation and function of IKK and IKK-related kinases. Science's STKE 2006, 2006:re13.
45. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nature Cell Biology 2004, 6:731-740.
46. Hamamoto R., Saloura V., Nakamura Y. Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nature Reviews. Cancer 2015, 15:110-124.
47. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
48. Hardwick J.C., Kodach L.L., Offerhaus G.J., van den Brink G.R. Bone morphogenetic protein signalling in colorectal cancer. Nature Reviews. Cancer 2008, 8:806-812.
49. Harris A.L. Hypoxia-A key regulatory factor in tumour growth. Nature Reviews. Cancer 2002, 2:38-47.
50. Harrison C.A., Wiater E., Gray P.C., Greenwald J., Choe S., Vale W. Modulation of activin and BMP signaling. Molecular and Cellular Endocrinology 2004, 225:19-24.
51. Haupt A., Joberty G., Bantscheff M., Frohlich H., Stehr H., Schweiger M.R., et al. Hsp90 inhibition differentially destabilises MAP kinase and TGF-β signalling components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer 2012, 12:38.
52. Hayes G.M., Carrigan P.E., Miller L.J. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Research 2007, 67:2072-2080.
53. He X.C., Zhang J., Tong W.G., Tawfik O., Ross J., Scoville D.H., et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-β-catenin signaling. Nature Genetics 2004, 36:1117-1121.
54. Herath N.I., Doecke J., Spanevello M.D., Leggett B.A., Boyd A.W. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. British Journal of Cancer 2009, 100:1095-1102.
55. Hoesel B., Schmid J.A. The complexity of NF-κB signaling in inflammation and cancer. Molecular Cancer 2013, 12:86.
56. Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A., Petersen G.M., et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nature Genetics 2001, 28:184-187.
57. Huang R., Huang D., Dai W., Yang F. Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancer. Molecular and Cellular Biochemistry 2015, 404:251-257.
58. Huntoon C.J., Nye M.D., Geng L., Peterson K.L., Flatten K.S., Haluska P., et al. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Cancer Research 2010, 70:8642-8650.
59. Hurst D.R., Mehta A., Moore B.P., Phadke P.A., Meehan W.J., Accavitti M.A., et al. Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. Biochemical and Biophysical Research Communications 2006, 348:1429-1435.
60. Hurst D.R., Welch D.R. Metastasis suppressor genes at the interface between the environment and tumor cell growth. International Review of Cell and Molecular Biology 2011, 286:107-180.
61. Hurst D.R., Welch D.R. Unraveling the enigmatic complexities of BRMS1-mediated metastasis suppression. FEBS Letters 2011, 585:3185-3190.
62. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradative pathway. Journal of Biological Chemistry 2002, 277:29936-29944.
63. Isaacs J.S., Jung Y.J., Neckers L. Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1α by modulating an Hsp90-dependent regulatory pathway. Journal of Biological Chemistry 2004, 279:16128-16135.
64. Jiang H.B., Yang T.J., Lu P., Ma Y.J. Gene expression profiling of gastric cancer. European Review for Medical and Pharmacological Sciences 2014, 18:2109-2115.
65. Khurana N., Bhattacharyya S. Hsp90, the concertmaster: Tuning transcription. Frontiers in Oncology 2015, 5:100.
66. Komori A., Sueoka E., Fujiki H., Ishii M., Kozu T. Association of MTG8 (ETO/CDR), a leukemia-related protein, with serine/threonine protein kinases and heat shock protein HSP90 in human hematopoietic cell lines. Japanese Journal of Cancer Research 1999, 90:60-68.
67. Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S., Collazos A., et al. Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration. PLoS One 2011, 6:e21732.
68. Lancet J.E., Gojo I., Burton M., Quinn M., Tighe S.M., Kersey K., et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010, 24:699-705.
69. Landen C.N., Kinch M.S., Sood A.K. EphA2 as a target for ovarian cancer therapy. Expert Opinion on Therapeutic Targets 2005, 9:1179-1187.
70. Le A., Cooper C.R., Gouw A.M., Dinavahi R., Maitra A., Deck L.M., et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:2037-2042.
71. Ledgerwood E.C., Morison I.M. Targeting the apoptosome for cancer therapy. Clinical Cancer Research 2009, 15:420-424.
72. Lewis J., Devin A., Miller A., Lin Y., Rodriguez Y., Neckers L., et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-κB activation. Journal of Biological Chemistry 2000, 275:10519-10526.
73. Light J.E., Koyama H., Minturn J.E., Ho R., Simpson A.M., Iyer R., et al. Clinical significance of NTRK family gene expression in neuroblastomas. Pediatric Blood & Cancer 2012, 59:226-232.
74. Lin R.K., Wang Y.C. Dysregulated transcriptional and post-translational control of DNA methyltransferases in cancer. Cell & Bioscience 2014, 4:46.
75. Lisabeth E.M., Falivelli G., Pasquale E.B. Eph receptor signaling and ephrins. Cold Spring Harbor Perspectives in Biology 2013, 5. a009159.
76. Liu W.M., Guerra-Vladusic F.K., Kurakata S., Lupu R., Kohwi-Shigematsu T. HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. Cancer Research 1999, 59:5695-5703.
77. Luo D., Wang Z., Wu J., Jiang C., Wu J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. BioMed Research International 2014, 2014:409272.
78. Mahajan K., Mahajan N.P. ACK1/TNK2 tyrosine kinase: Molecular signaling and evolving role in cancers. Oncogene 2015, 34:4162-4167.
79. Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: Role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Research 2005, 65:10514-10523.
80. Maloney A., Clarke P.A., Naaby-Hansen S., Stein R., Koopman J.O., Akpan A., et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Research 2007, 67:3239-3253.
81. Mao W., Luis E., Ross S., Silva J., Tan C., Crowley C., et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Research 2004, 64:781-788.
82. May W.S., Hoare K., Hoare S., Reinhard M.K., Lee Y.J., Oh S.P. Tnk1/Kos1: A novel tumor suppressor. Transactions of the American Clinical and Climatological Association 2010, 121:281-292. discussion 292-293.
83. Melotte V., Qu X., Ongenaert M., van Criekinge W., de Bruine A.P., Baldwin H.S., et al. The N-myc downstream regulated gene (NDRG) family: Diverse functions, multiple applications. FASEB Journal 2010, 24:4153-4166.
84. Meyer T., Xu L., Chang J., Liu E.T., Craven R.J., Cance W.G. Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase. International Journal of Cancer 2003, 104:139-146.
85. Michie A.M., McCaig A.M., Nakagawa R., Vukovic M. Death-associated protein kinase (DAPK) and signal transduction: Regulation in cancer. The FEBS Journal 2010, 277:74-80.
86. Mihai C., Chotani M., Elton T.S., Agarwal G. Mapping of DDR1 distribution and oligomerization on the cell surface by FRET microscopy. Journal of Molecular Biology 2009, 385:432-445.
87. Moniz L., Dutt P., Haider N., Stambolic V. Nek family of kinases in cell cycle, checkpoint control and cancer. Cell Division 2011, 6:18.
88. Mujcic H., Hill R.P., Koritzinsky M., Wouters B.G. Hypoxia signaling and the metastatic phenotype. Current Molecular Medicine 2014, 14:565-579.
89. Namiki T., Tanemura A., Valencia J.C., Coelho S.G., Passeron T., Kawaguchi M., et al. AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:6597-6602.
90. Namiki T., Yaguchi T., Nakamura K., Valencia J.C., Coelho S.G., Yin L., et al. NUAK2 amplification coupled with PTEN deficiency promote melanoma development via CDK activation. Cancer Research 2015, 75:2708-2715.
91. Nathan D.F., Vos M.H., Lindquist S. In vivo functions of the Saccharomyces cerevisiae Hsp90 chaperone. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:12949-12956.
92. Neckers L., Workman P. Hsp90 molecular chaperone inhibitors: Are we there yet?. Clinical Cancer Research 2012, 18:64-76.
93. Pandey P., Saleh A., Nakazawa A., Kumar S., Srinivasula S.M., Kumar V., et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. The EMBO Journal 2000, 19:4310-4322.
94. Pasquale E.B. Eph receptor signalling casts a wide net on cell behaviour. Nature Reviews. Molecular Cell Biology 2005, 6:462-475.
95. Pawlus M.R., Wang L., Hu C.J. STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene 2014, 33:1670-1679.
96. Peterson L.F., Zhang D.E. The 8;21 translocation in leukemogenesis. Oncogene 2004, 23:4255-4262.
97. Pixley F.J., Stanley E.R. CSF-1 regulation of the wandering macrophage: Complexity in action. Trends in Cell Biology 2004, 14:628-638.
98. Purkayastha B.P., Roy J.K. Cancer cell metabolism and developmental homeodomain/POU domain transcription factors: A connecting link. Cancer Letters 2015, 356:315-319.
99. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
100. Raftopoulou M., Hall A. Cell migration: Rho GTPases lead the way. Developmental Biology 2004, 265:23-32.
101. Renoir J.M. Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches. Steroids 2012, 77:1249-1261.
102. Rhyasen G.W., Starczynowski D.T. IRAK signalling in cancer. British Journal of Cancer 2015, 112:232-237.
103. Saleh A., Srinivasula S.M., Balkir L., Robbins P.D., Alnemri E.S. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nature Cell Biology 2000, 2:476-483.
104. Senapedis W.T., Baloglu E., Landesman Y. Clinical translation of nuclear export inhibitors in cancer. Seminars in Cancer Biology 2014, 27:74-86.
105. Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Research 2003, 13:2498-2504.
106. Shen R.R., Hahn W.C. Emerging roles for the non-canonical IKKs in cancer. Oncogene 2011, 30:631-641.
107. Shi Q., Song X., Wang J., Gu J., Zhang W., Hu J., et al. FRK inhibits migration and invasion of human glioma cells by promoting N-cadherin/β-catenin complex formation. Journal of Molecular Neuroscience 2015, 55:32-41.
108. Shrivastava A., Radziejewski C., Campbell E., Kovac L., McGlynn M., Ryan T.E., et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Molecular Cell 1997, 1:25-34.
109. Singel S.M., Batten K., Cornelius C., Jia G., Fasciani G., Barron S.L., et al. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-κB and c-Jun N-terminal kinase pathways. Breast Cancer Research 2014, 16:R28.
110. Slipicevic A., Holm R., Emilsen E., Ree Rosnes A.K., Welch D.R., Malandsmo G.M., et al. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival. BMC Cancer 2012, 12:73.
111. Sobolesky P.M., Moussa O. The role of β-arrestins in cancer. Progress in Molecular Biology and Translational Science 2013, 118:395-411.
112. Soldevilla B., Millan C.S., Bonilla F., Dominguez G. The TP73 complex network: Ready for clinical translation in cancer?. Genes, Chromosomes & Cancer 2013, 52:989-1006.
113. Stephens P., Edkins S., Davies H., Greenman C., Cox C., Hunter C., et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nature Genetics 2005, 37:590-592.
114. Stopa N., Krebs J.E., Shechter D. The PRMT5 arginine methyltransferase: Many roles in development, cancer and beyond. Cellular and Molecular Life Sciences 2015, 72:2041-2059.
115. Stransky N., Cerami E., Schalm S., Kim J.L., Lengauer C. The landscape of kinase fusions in cancer. Nature Communications 2014, 5:4846.
116. Su G.H., Bansal R., Murphy K.M., Montgomery E., Yeo C.J., Hruban R.H., et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:3254-3257.
117. Subramaniam D., Thombre R., Dhar A., Anant S. DNA methyltransferases: A novel target for prevention and therapy. Frontiers in Oncology 2014, 4:80.
118. Sullivan A.R., Pixley F.J. CSF-1R signaling in health and disease: A focus on the mammary gland. Journal of Mammary Gland Biology and Neoplasia 2014, 19:149-159.
119. Sun X., Gao L., Chien H.Y., Li W.C., Zhao J. The regulation and function of the NUAK family. Journal of Molecular Endocrinology 2013, 51:R15-R22.
120. Sun L., Hartson S.D., Matts R.L. Identification of proteins associated with Aha1 in HeLa cells by quantitative proteomics. Biochimica et Biophysica Acta 2015, 1854:365-380.
121. Taipale M., Krykbaeva I., Koeva M., Kayatekin C., Westover K.D., Karras G.I., et al. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 2012, 150:987-1001.
122. Tandon M., Vemula S.V., Mittal S.K. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opinion on Therapeutic Targets 2011, 15:31-51.
123. Tiedemann R.E., Zhu Y.X., Schmidt J., Yin H., Shi C.-X., Que Q., et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010, 115:1594-1604.
124. Toma M.I., Erdmann K., Diezel M., Meinhardt M., Zastrow S., Fuessel S., et al. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. PLoS One 2014, 9:e102262.
125. Tu L.C., Yan X., Hood L., Lin B. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Molecular and Cellular Proteomics 2007, 6:575-588.
126. Turley H., Wu L., Canamero M., Gatter K.C., Hickson I.D. The distribution and expression of the Bloom's syndrome gene product in normal and neoplastic human cells. British Journal of Cancer 2001, 85:261-265.
127. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochemical Pharmacology 2012, 83:1021-1032.
128. Ueda K., Xu J., Morimoto H., Kawabe A., Imaoka S. MafG controls the hypoxic response of cells by accumulating HIF-1α in the nuclei. FEBS Letters 2008, 582:2357-2364.
129. Valiathan R.R., Marco M., Leitinger B., Kleer C.G., Fridman R. Discoidin domain receptor tyrosine kinases: New players in cancer progression. Cancer Metastasis Reviews 2012, 31:295-321.
130. Verhelst K., Verstrepen L., Carpentier I., Beyaert R. IkB kinase e (IKKe): A therapeutic target in inflammation and cancer. Biochemical Pharmacology 2013, 85:873-880.
131. Vogel W., Gish G.D., Alves F., Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Molecular Cell 1997, 1:13-23.
132. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
133. Vrzalikova K., Woodman C.B., Murray P.G. BLIMP1α, the master regulator of plasma cell differentiation is a tumor supressor gene in B cell lymphomas. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2012, 156:1-6.
134. Williams M.D., Zhang X., Belton A.S., Xian L., Huso T., Park J.J., et al. HMGA1 drives metabolic reprogramming of intestinal epithelium during hyperproliferation, polyposis, and colorectal carcinogenesis. Journal of Proteome Research 2015, 14:1420-1431.
135. Wu Z., Moghaddas Gholami A., Kuster B. Systematic identification of the HSP90 candidate regulated proteome. Molecular and Cellular Proteomics 2012, 11. M111.016675.
136. Xia L.M., Huang W.J., Wang B., Liu M., Zhang Q., Yan W., et al. Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1. Journal of Cellular Biochemistry 2009, 106:247-256.
137. Xiao K., McClatchy D.B., Shukla A.K., Zhao Y., Chen M., Shenoy S.K., et al. Functional specialization of β-arrestin interactions revealed by proteomic analysis. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:12011-12016.
138. Yang Y., Bedford M.T. Protein arginine methyltransferases and cancer. Nature Reviews. Cancer 2013, 13:37-50.
139. Yang G., Thompson M.A., Brandt S.J., Hiebert S.W. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 2007, 26:91-101.
140. Yuan S., Akey C.W. Apoptosome structure, assembly, and procaspase activation. Structure 2013, 21:501-515.
141. Zhang D., Lin J., Han J. Receptor-interacting protein (RIP) kinase family. Cellular & Molecular Immunology 2010, 7:243-249.
142. Zhang L., Nephew K.P., Gallagher P.J. Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes. Journal of Biological Chemistry 2007, 282:11795-11804.
143. Zhang J., Xu E., Chen X. TAp73 protein stability is controlled by histone deacetylase 1 via regulation of Hsp90 chaperone function. Journal of Biological Chemistry 2013, 288:7727-7737.
144. Zhong X.Y., Ding J.H., Adams J.A., Ghosh G., Fu X.D. Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes & Development 2009, 23:482-495.
145. Zhou Q., Agoston A.T., Atadja P., Nelson W.G., Davidson N.E. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Molecular Cancer Research 2008, 6:873-883.
146. Zhou B., Li Y., Deng Q., Wang H., Wang Y., Cai B., et al. SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. Molecular and Cellular Biochemistry 2013, 379:191-199.
147. Zhou Y., Sun H., Danila D.C., Johnson S.R., Sigai D.P., Zhang X., et al. Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Molecular Endocrinology 2000, 14:2066-2075.